| Name | Title | Contact Details |
|---|
Medical Center of McKinney (MCM) is a growing 260-bed hospital with a 90-year history of serving the health care needs of McKinney and the surrounding communities. Over the past several years, MCM has strengthened its medical foundations by adding two new surgical robots, a newly remodeled labor and delivery suites, a Level III Neonatal Intensive Care Unit (NICU) and an advanced biplane Catheterization (cath) lab to treat heart rhythm disorders. Medical Center of McKinney will be expanding its services to the community with the addition of a new off-campus emergency department at 380 & Custer in 2015.
Senior Network, The is a Stamford, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Bleu Chateau Assisted Living is a Burbank, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
In every industry there is a company that thinks, and does things, differently. In employee group benefits, GroupHEALTH Benefits Solutions™ is that company. GroupHEALTH is transforming the way Canadians experience benefits by developing and delivering the most affordable, configurable, and usable benefit solutions to businesses across Canada. Leaders in employee benefits plans and group insurance, the GroupHEALTH Family of Companies has more than 500 employees in offices in Vancouver, Surrey, Calgary, Edmonton, Etobicoke, Woodbridge, and Barrie. With annual premiums exceeding $500 million and over $5 billion in pension assets under management, GroupHEALTH supplies market leading employee benefit services to more than 4,000 client organizations across Canada in both the public and private sectors, supporting more than 450,000 Canadians and their families.
HedgePath Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize innovative therapeutics for patients with cancer. The Company may also explore acquiring or licensing innovative therapeutics addressing unmet needs and orphan indications beyond cancer. We are focused on the development of therapies for more than one type of cancer, with initial emphasis in the U.S. market, based upon repurposing the currently marketed antifungal drug itraconazole for new indications in oncology.